Surrozen, Inc. (SRZN) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
N/A
—
5yr avg: 0.94
30Y Low0.3·High2.1
ROE
↓
N/A
—
5yr avg: -237.3%
30Y Low-85%·High-39%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SRZN Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Surrozen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $230M | $169M | $42M | $19M | $20M | $226M | — | — |
| Enterprise Value | $147M | $86M | $16M | $-13694809 | $1M | $200M | — | — |
| P/E Ratio → | -0.95 | — | — | — | — | — | — | — |
| P/S Ratio | 66.13 | 48.61 | 3.95 | — | 1.62 | — | — | — |
| P/B Ratio | — | — | — | 0.50 | 0.27 | 2.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SRZN EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 24.85 | 1.50 | — | 0.09 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
SRZN Profitability
Margins and return-on-capital ratios measuring operating efficiency
Surrozen, Inc. earns an operating margin of -1210.6%. Operating margins have compressed from -239.7% to -1210.6% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 84.6% | 84.6% | 100.0% | — | 73.8% | — | — | — |
| Operating Margin | -1210.6% | -1210.6% | -239.7% | — | -354.7% | — | — | — |
| Net Profit Margin | -6960.8% | -6960.8% | -596.6% | — | -288.0% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -767.9% | -75.6% | -38.8% | -66.9% | -85.1% | -82.9% |
| ROA | -328.9% | -328.9% | -134.5% | -63.5% | -31.8% | -52.7% | -62.4% | -57.3% |
| ROIC | — | — | — | -110.4% | -47.1% | -76.7% | -149.6% | — |
| ROCE | -64.8% | -64.8% | -63.8% | -77.2% | -43.6% | -61.0% | -70.3% | -65.1% |
SRZN Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $89M exceeds total debt of $7M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.09 | 0.07 | 0.07 | 0.20 | 0.36 |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.86 | -0.25 | -0.23 | -0.54 | -0.63 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — |
Net cash position: cash ($89M) exceeds total debt ($7M)
SRZN Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Surrozen, Inc.'s current ratio of 9.22x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.75x to 9.22x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.22 | 9.22 | 5.32 | 5.75 | 8.35 | 7.75 | 6.90 | 7.54 |
| Quick Ratio | 9.22 | 9.22 | 5.32 | 5.75 | 8.35 | 7.75 | 6.90 | 7.54 |
| Cash Ratio | 8.99 | 8.99 | 4.73 | 5.04 | 7.79 | 7.50 | 6.76 | 7.46 |
| Asset Turnover | — | 0.04 | 0.22 | — | 0.14 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 21.83 | 87.05 | — | 57.76 | — | — | — |
SRZN Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Surrozen, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 12.9% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 12.9% | 0.0% | — | — |
| Shares Outstanding | — | $7M | $3M | $2M | $2M | $2M | $795599 | $393311 |
Peer Comparison
Compare SRZN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SRZNYou | $230M | -0.9 | — | — | 84.6% | -1210.6% | — | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRTA | $567M | -2.3 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 VRTX | $108B | 27.7 | 21.5 | 33.8 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 ALNY | $39B | 127.0 | 70.2 | 84.8 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 INCY | $20B | 15.3 | 11.5 | 14.4 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
See SRZN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRZN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRZN vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonSRZN — Frequently Asked Questions
Quick answers to the most common questions about buying SRZN stock.
What is Surrozen, Inc.'s P/E ratio?
Surrozen, Inc.'s current P/E ratio is -0.9x. This places it at the 50th percentile of its historical range.
Is SRZN stock overvalued?
Based on historical data, Surrozen, Inc. is trading at a P/E of -0.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Surrozen, Inc.'s profit margins?
Surrozen, Inc. has 84.6% gross margin and -1210.6% operating margin.